Ignite Creation Date:
2024-05-06 @ 10:46 AM
Last Modification Date:
2024-10-26 @ 12:35 PM
Study NCT ID:
NCT03347383
Status:
COMPLETED
Last Update Posted:
2024-03-07
First Post:
2017-11-15
Brief Title:
Clinical Trial Investigating the Combination Therapy With Luminor DCB and iVolution Stent in TASC C and D Femoropopliteal Lesions
Sponsor:
ID3 Medical
Organization:
ID3 Medical
Study Overview
Official Title:
Physician Initiated Prospective Non-randomized Belgian Multi-center Trial Investigating the Safety and Efficacy of the Treatment With the LumINor DCB and The IvolutioN Stent of iVascular in TASC C and D Femoropopliteal Atherosclerotic Disease
Status:
COMPLETED
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TINTIN
Brief Summary:
The TINTIN study investigates the safety and efficacy of the combination therapy with the Luminor drug coated balloon DCB and the iVolution stent in the treatment of TASC C and D femoropopliteal lesions An expected total of 100 patients will be treated in the scope of this study The lesion is located within the native superficial femoral artery andor the popliteal artery Prior to dilatation with the Luminor DCB pre-dilatation with the Oceanus balloon is mandatory After dilatation with the Luminor DCB stenting with the iVolution stent need to be performed Post-dilatation can be performed according to the physicians discretion Patients will be invited for a follow-up visit at 1 6 12 24 36 48 and 60 month post-procedure The primary efficacy endpoint of the study is defined as the freedom from clinically-driven target lesion revascularization TLR at 12 months Secondary endpoints include primary patency rate at 6 and 12 months freedom from clinically-driven TLR at 6 24 36 48 and 60 months clinical success at 1 6 12 24 36 48 and 60 months and freedom from serious adverse events at pre-discharge 1 6 12 24 36 48 and 60 months follow-up
Detailed Description:
The objective of this clinical investigation is to evaluate in a controlled setting the long-term safety and efficacy of the combination therapy with the Luminor DCB and the iVolution stent post CE-certification and according to the indications of the Instructions for use IFU with focus on the treatment of TASC C and D femoropopliteal atherosclerotic lesions
Patients will be selected based on the investigators assessment evaluation of the underlying disease and the eligibility criteria The patients medical condition should be stable with no underlying medical condition which would prevent them from performing the required testing or from completing the study Patients should also be geographically stable willing and able to cooperate in this clinical study and remain available for long-term follow-up A patient is considered enrolled in the study after obtaining the patients informed consent if there is full compliance with the study eligibility criteria and after successful guidewire passage through the study target lesion
Prior to the index procedure the following tests and clinical data will be collected informed consent for data collection demographics medical history medication record physical examination clinical category of chronic limb ischemia Rutherford category and resting ankle-brachial index ABI
During the procedure the vascular access can be achieved to the investigators standard clinical practice After successful lesion passage diagnostic angiography of the lesion area and distal run-off is performed and angiographic measurements vessel diameter percentage stenosis and lesion length are collected All inflow-limiting lesion will be treated according to the investigators standard clinical practice before treatment of the target lesion Pre-dilatation of the target lesion is mandatory with the Oceanus balloon After pre-dilatation a least one Luminor DCB will be inflated and at least 1 iVolution stent will be deployed at the target lesion At the physicians discretion post-dilatation can be performed No other adjunctive therapies atherectomy laser are allowed The complete femoropopliteal vasculature should be treated in one single session staged interventions are not allowed All outflow-limiting lesions must be treated according to the hospital treatment standard
The regular follow-ups are necessary to monitor the condition of the patient and the procedure Patients will be invited for a follow-up visit at 1 6 12 24 36 48 and 60 months after the index procedure The 24 36 48 and 60 month follow-up can be conducted via a phone call The following data will be collected during these follow-up visit medication record physical examination rutherford categorization ABI and color flow doppler ultrasound
Patients will be selected based on the investigators assessment evaluation of the underlying disease and the eligibility criteria The patients medical condition should be stable with no underlying medical condition which would prevent them from performing the required testing or from completing the study Patients should also be geographically stable willing and able to cooperate in this clinical study and remain available for long-term follow-up A patient is considered enrolled in the study after obtaining the patients informed consent if there is full compliance with the study eligibility criteria and after successful guidewire passage through the study target lesion
Prior to the index procedure the following tests and clinical data will be collected informed consent for data collection demographics medical history medication record physical examination clinical category of chronic limb ischemia Rutherford category and resting ankle-brachial index ABI
During the procedure the vascular access can be achieved to the investigators standard clinical practice After successful lesion passage diagnostic angiography of the lesion area and distal run-off is performed and angiographic measurements vessel diameter percentage stenosis and lesion length are collected All inflow-limiting lesion will be treated according to the investigators standard clinical practice before treatment of the target lesion Pre-dilatation of the target lesion is mandatory with the Oceanus balloon After pre-dilatation a least one Luminor DCB will be inflated and at least 1 iVolution stent will be deployed at the target lesion At the physicians discretion post-dilatation can be performed No other adjunctive therapies atherectomy laser are allowed The complete femoropopliteal vasculature should be treated in one single session staged interventions are not allowed All outflow-limiting lesions must be treated according to the hospital treatment standard
The regular follow-ups are necessary to monitor the condition of the patient and the procedure Patients will be invited for a follow-up visit at 1 6 12 24 36 48 and 60 months after the index procedure The 24 36 48 and 60 month follow-up can be conducted via a phone call The following data will be collected during these follow-up visit medication record physical examination rutherford categorization ABI and color flow doppler ultrasound
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None